Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
Pharma News
Work on another Sanofi drug delayed by manufacturing issues
It turns out that the FDA complete response letter (CRL) Sanofi and partner Regeneron recently received for their experimental IL-6 inhibitor, and Humira competitor, sarilumab is not the only ...
Pfizer to close two manufacturing sites in UK with 370 job losses
US drugs giant Pfizer will shut two of its three manufacturing plants in the UK in the next four years, putting 370 jobs at risk.
With Prop 61's defeat, drug-pricing foes can forget state-level action
California has been ground zero in the industry battle against state drug pricing laws, and by a safe margin Tuesday, pharma came out ahead on the contentious Prop 61.
Discovery of Cerecor Drug Candidate CERC-611 (LY3130481) Published in Nature Medicine
BALTIMORE, MD, USA I November 8, 2016 I Cerecor, Inc.
Memantine plus sertraline effective for major depressive disorder
HealthDay News — The combination of memantine plus sertraline is efficacious for major depressive disorder, according to a study published in the Journal of Clinical Pharmacy and Therapeutics.
Ketofol an alternative deep sedative
Australian emergency medicine researchers have successfully trialled an alternative deep sedative for patients in the emergency department.
Roche's Tecentriq-based melanoma combos leapfrog into pivotal trials after promising PhIb results
Cheered by “extraordinarily high” efficacy in chemo-free combo studies, Roche is powering into late-stage trials with two different melanoma-fighting cocktails based on its brand-new immunotherapy...
Actelion announces positive results of the MERIT study with macitentan in patients with chronic thromboembolic pulmonary hypertension
ALLSCHWIL/BASEL, Switzerland November 7, 2016 I Actelion Ltd (SIX.
Regorafenib from Bayer Submitted to Health Authorities Seeking Approval in Second-Line Treatment of Liver Cancer
BERLIN, Germany I November 7, 2016 I Bayer today announced the submission of applications to extend the marketing authorization for its oral multi-kinase inhibitor regorafenib in the U.
Pancreatic cancer set to become third biggest cancer killer in EU next year
The number of deaths from pancreatic cancer will overtake breast cancer mortality rates in the EU in 2017, a study has found.
Drugmakers under fire for suspected US price fixing
Two prominent US lawmakers on Thursday called on US federal antitrust regulators to probe whether Sanofi SA, Eli Lilly and Co, Merck & Co Inc and Novo Nordisk A/S colluded to set prices for insuli...
Why is Valeant's 'blockbuster' libido drug Addyi a dud? Shoddy marketing, investor lawsuit claims
When Valeant bought Sprout Pharmaceuticals and its controversial female libido drug Addyi, it agreed to a marketing blitz that would bring royalties to Sprout's former shareholders.
593
594
595
596
597
598
599
600
601
